Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Source: CNBC
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 45.800
Low
42.00
Averages
54.67
High
70.00
Current: 45.800
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Reports Revenue Growth Amid Shrinking Margins
- Revenue Growth: Hims & Hers reported first-quarter 2026 revenue of $608.1 million, a 4% year-over-year increase, indicating continued subscriber growth across its weight-loss, sexual health, dermatology, and primary care sectors, despite profitability challenges.
- Profit Decline: The company posted a net loss of $92.1 million compared to a net income of $49.5 million a year earlier, with adjusted EBITDA falling from $91.1 million to $44.3 million and gross margin shrinking from 73% to 65%, highlighting the economic pressures from its strategic shift.
- Strategic Shift: Hims transitioned from high-margin compounded GLP-1 weight-loss drugs to branded products like Novo Nordisk's, which reduced regulatory risks but compressed margins and increased operating costs, resulting in a more than 12% drop in stock price following the earnings release.
- International Expansion: The acquisition of ZAVA allows Hims to tap into the European market with approximately $100 million in annual revenue and an established telemedicine infrastructure, while the company plans to expand into hormone optimization and preventative diagnostics, despite facing high valuation and execution risks.
See More
Investment Opportunities in Biogen and Novo Nordisk: A Comparative Analysis
- Biogen's Turnaround Potential: Biogen focuses on neurology, and despite declining revenue from its multiple sclerosis products, Q1 2025 revenue rose 2% year-over-year to $2.5 billion, with Leqembi sales increasing 74% to $168 million, indicating significant market potential in Alzheimer's treatment.
- Acquisition-Driven Pipeline Expansion: By acquiring Reata Pharmaceuticals for $7.3 billion and Apellis Pharmaceuticals for $5.6 billion, Biogen has introduced new drugs like Skyclarys and Empaveli, with projected sales growth in the low to mid-teens through 2028, enhancing its product diversity.
- Novo Nordisk's Growth Engine: Novo Nordisk excels in diabetes and obesity markets, reporting Q1 2025 revenue of 96.8 billion DKK (approximately $15.3 billion), a 24% year-over-year increase, driven by high demand for its GLP-1 drugs, prompting the company to expand manufacturing capacity for sustained competitiveness.
- Diversification Strategy: Novo Nordisk's $4.7 billion acquisition of Akero Therapeutics strengthens its metabolic treatment portfolio, while label expansions for its GLP-1 therapies in cardiovascular and chronic kidney disease treatments enhance clinical versatility, solidifying its competitive position in the healthcare insurance market.
See More
Hantavirus Outbreak Raises Public Health Concerns
- Outbreak Overview: As of Tuesday, the WHO reported 11 cases linked to the hantavirus outbreak, with 9 confirmed cases including 3 deaths; while no positive cases have been found in the U.S., public concern is rising significantly.
- Monitoring Measures: In the U.S., 18 individuals are being monitored across Nebraska and Atlanta for potential exposure, and although more cases may emerge, experts assert that the risk remains low due to the hantavirus's limited transmissibility.
- CDC Response Capability: While the CDC appears to have the outbreak under control, experts warn that past cuts to the agency and the withdrawal from the WHO may undermine the U.S.'s ability to respond to future infectious disease threats, especially against more contagious pathogens.
- Vaccine Development Progress: Moderna's shares surged approximately 12% after confirming it is researching a potential vaccine for hantavirus, although specific treatments are still years away, this development may provide hope for future public health responses.
See More
Eli Lilly Leads the Weight Loss Drug Market
- Market Leadership: Eli Lilly is positioned to lead the weight loss drug market, projected to reach $100 billion in the next decade from a current value of $40 billion, indicating strong performance in a rapidly growing sector.
- Significant Sales Growth: In the recent quarter, Mounjaro and Zepbound generated over $12 billion in total sales, reflecting robust consumer demand for GLP-1 drugs and the company's competitive edge in this field.
- New Product Launch: Lilly received FDA approval for its oral weight loss drug Foundayo, treating 20,000 patients in its first month, showcasing strong appeal among new users and potentially providing new growth avenues for the company.
- Managing Competitive Risks: While new products from Novo Nordisk and other competitors pose risks to Zepbound sales, the introduction of Foundayo may broaden the potential audience for GLP-1 drugs, creating new market opportunities for Eli Lilly.
See More
US-India Relations Face New Challenges Amidst US-China Summit
- Tension in US-India Relations: The shift in the Trump administration's China policy has strained US-India relations, with experts noting India's concerns that the US may prioritize China as the main negotiating partner, thereby diminishing India's strategic role in the Indo-Pacific.
- Need for Enhanced Strategic Value: To counter potential marginalization, India must establish more tangible cooperation with the US in sectors such as defense, maritime security, and critical minerals, thereby enhancing its strategic value and ensuring its importance in US-China relations.
- Changes in Trade Policy: The Trump administration's trade policy has become more transactional, with a 25% penalty tariff imposed on India last year for allegedly profiting from cheap Russian oil, further deteriorating bilateral relations.
- Concerns Over G2 Concept: India's attention to the US-China summit has intensified, with fears that the so-called 'G2' concept may marginalize middle powers like India, impacting its voice and influence in international affairs.
See More
Novo Nordisk Added as Long Idea with 52%-117% Upside Potential
- Market Mispricing: Hedgeye analyst Tom Tobin highlighted that Novo Nordisk's current price of $46 undervalues a $50 million patient US market opportunity, with the Wegovy pill launch expected to outperform previous obesity drugs, indicating a significant market misunderstanding of its potential.
- Duopoly Establishment: By aggressively cutting prices, Novo and Lilly have effectively secured a duopoly, raising barriers to market entry; while this strategy compresses short-term margins, it enhances long-term market share stability, showcasing the foresight of the company's strategy.
- Growth Forecast: Tobin's model predicts 3.6 million monthly prescriptions by 2026, with an estimated EPS of $5.06 for 2027, significantly above the consensus estimate of $3.55, indicating strong future growth potential for the company.
- Price Target: With a 14x P/E ratio, Novo Nordisk's target price is set at $70, and at a re-rated 20x, it could reach $100, implying a potential upside of 52%-117%, reflecting investor optimism about its future performance.
See More
Hims & Hers Reports Revenue Growth Amid Shrinking Margins
- Revenue Growth: Hims & Hers reported first-quarter 2026 revenue of $608.1 million, a 4% year-over-year increase, indicating continued subscriber growth across its weight-loss, sexual health, dermatology, and primary care sectors, despite profitability challenges.
- Profit Decline: The company posted a net loss of $92.1 million compared to a net income of $49.5 million a year earlier, with adjusted EBITDA falling from $91.1 million to $44.3 million and gross margin shrinking from 73% to 65%, highlighting the economic pressures from its strategic shift.
- Strategic Shift: Hims transitioned from high-margin compounded GLP-1 weight-loss drugs to branded products like Novo Nordisk's, which reduced regulatory risks but compressed margins and increased operating costs, resulting in a more than 12% drop in stock price following the earnings release.
- International Expansion: The acquisition of ZAVA allows Hims to tap into the European market with approximately $100 million in annual revenue and an established telemedicine infrastructure, while the company plans to expand into hormone optimization and preventative diagnostics, despite facing high valuation and execution risks.
See More
Investment Opportunities in Biogen and Novo Nordisk: A Comparative Analysis
- Biogen's Turnaround Potential: Biogen focuses on neurology, and despite declining revenue from its multiple sclerosis products, Q1 2025 revenue rose 2% year-over-year to $2.5 billion, with Leqembi sales increasing 74% to $168 million, indicating significant market potential in Alzheimer's treatment.
- Acquisition-Driven Pipeline Expansion: By acquiring Reata Pharmaceuticals for $7.3 billion and Apellis Pharmaceuticals for $5.6 billion, Biogen has introduced new drugs like Skyclarys and Empaveli, with projected sales growth in the low to mid-teens through 2028, enhancing its product diversity.
- Novo Nordisk's Growth Engine: Novo Nordisk excels in diabetes and obesity markets, reporting Q1 2025 revenue of 96.8 billion DKK (approximately $15.3 billion), a 24% year-over-year increase, driven by high demand for its GLP-1 drugs, prompting the company to expand manufacturing capacity for sustained competitiveness.
- Diversification Strategy: Novo Nordisk's $4.7 billion acquisition of Akero Therapeutics strengthens its metabolic treatment portfolio, while label expansions for its GLP-1 therapies in cardiovascular and chronic kidney disease treatments enhance clinical versatility, solidifying its competitive position in the healthcare insurance market.
See More
Hantavirus Outbreak Raises Public Health Concerns
- Outbreak Overview: As of Tuesday, the WHO reported 11 cases linked to the hantavirus outbreak, with 9 confirmed cases including 3 deaths; while no positive cases have been found in the U.S., public concern is rising significantly.
- Monitoring Measures: In the U.S., 18 individuals are being monitored across Nebraska and Atlanta for potential exposure, and although more cases may emerge, experts assert that the risk remains low due to the hantavirus's limited transmissibility.
- CDC Response Capability: While the CDC appears to have the outbreak under control, experts warn that past cuts to the agency and the withdrawal from the WHO may undermine the U.S.'s ability to respond to future infectious disease threats, especially against more contagious pathogens.
- Vaccine Development Progress: Moderna's shares surged approximately 12% after confirming it is researching a potential vaccine for hantavirus, although specific treatments are still years away, this development may provide hope for future public health responses.
See More
Eli Lilly Leads the Weight Loss Drug Market
- Market Leadership: Eli Lilly is positioned to lead the weight loss drug market, projected to reach $100 billion in the next decade from a current value of $40 billion, indicating strong performance in a rapidly growing sector.
- Significant Sales Growth: In the recent quarter, Mounjaro and Zepbound generated over $12 billion in total sales, reflecting robust consumer demand for GLP-1 drugs and the company's competitive edge in this field.
- New Product Launch: Lilly received FDA approval for its oral weight loss drug Foundayo, treating 20,000 patients in its first month, showcasing strong appeal among new users and potentially providing new growth avenues for the company.
- Managing Competitive Risks: While new products from Novo Nordisk and other competitors pose risks to Zepbound sales, the introduction of Foundayo may broaden the potential audience for GLP-1 drugs, creating new market opportunities for Eli Lilly.
See More
US-India Relations Face New Challenges Amidst US-China Summit
- Tension in US-India Relations: The shift in the Trump administration's China policy has strained US-India relations, with experts noting India's concerns that the US may prioritize China as the main negotiating partner, thereby diminishing India's strategic role in the Indo-Pacific.
- Need for Enhanced Strategic Value: To counter potential marginalization, India must establish more tangible cooperation with the US in sectors such as defense, maritime security, and critical minerals, thereby enhancing its strategic value and ensuring its importance in US-China relations.
- Changes in Trade Policy: The Trump administration's trade policy has become more transactional, with a 25% penalty tariff imposed on India last year for allegedly profiting from cheap Russian oil, further deteriorating bilateral relations.
- Concerns Over G2 Concept: India's attention to the US-China summit has intensified, with fears that the so-called 'G2' concept may marginalize middle powers like India, impacting its voice and influence in international affairs.
See More
Novo Nordisk Added as Long Idea with 52%-117% Upside Potential
- Market Mispricing: Hedgeye analyst Tom Tobin highlighted that Novo Nordisk's current price of $46 undervalues a $50 million patient US market opportunity, with the Wegovy pill launch expected to outperform previous obesity drugs, indicating a significant market misunderstanding of its potential.
- Duopoly Establishment: By aggressively cutting prices, Novo and Lilly have effectively secured a duopoly, raising barriers to market entry; while this strategy compresses short-term margins, it enhances long-term market share stability, showcasing the foresight of the company's strategy.
- Growth Forecast: Tobin's model predicts 3.6 million monthly prescriptions by 2026, with an estimated EPS of $5.06 for 2027, significantly above the consensus estimate of $3.55, indicating strong future growth potential for the company.
- Price Target: With a 14x P/E ratio, Novo Nordisk's target price is set at $70, and at a re-rated 20x, it could reach $100, implying a potential upside of 52%-117%, reflecting investor optimism about its future performance.
See More
